Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: The protective effects of pomegranate with its active component punicalagin

Antioxidants and Redox Signaling

Volumn 21, Issue 11, 2014, Pages 1557-1570

  Zou, Xuan ^a   Yan, Chunhong ^a   Shi, Yujie ^b   Cao, Ke ^a   Xu, Jie ^a   Wang, Xun ^a   Chen, Cong ^a   Luo, Cheng ^a   Li, Yuan ^a   Gao, Jing ^a   Pang, Wentao ^c   Zhao, Jialong ^c   Zhao, Fei ^c   Li, Hao ^a   Zheng, Adi ^a   Sun, Wenyan ^a   Long, Jiangang ^a   Szeto, Ignatius Man Yau ^b   Zhao, Youyou ^b   Dong, Zhizhong ^b   Zhang, Peifang ^b   Wang, Junkuan ^b   Lu, Wuyuan ^a   Zhang, Yong ^a,c   Liu, Jiankang ^a,c   Feng, Zhihui ^a   more..

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

^c TIANJIN UNIVERSITY OF SPORT   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE LYASE; ALANINE AMINOTRANSFERASE; CHOLESTEROL; DIACYLGLYCEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; LIVER PROTECTIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PALMITIC ACID; POMEGRANATE EXTRACT; PROTEIN PRECURSOR; PUNICALAGIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; PLANT EXTRACT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; FOOD INTAKE; HEPG2 CELL LINE; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; LIVER CELL; LIVER PROTECTION; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATION; OXIDATIVE STRESS; POMEGRANATE; RAT; RISK FACTOR; WEIGHT GAIN; ANIMAL; BLOOD; CHEMISTRY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HUMAN; INFLAMMATION; LIPID METABOLISM; LIVER; LYTHRACEAE; MALE; METABOLISM; MITOCHONDRION; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALS; BODY WEIGHT; CHOLESTEROL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HEP G2 CELLS; HUMANS; HYDROLYZABLE TANNINS; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MITOCHONDRIA; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATIVE STRESS; PLANT EXTRACTS; PUNICACEAE; RATS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 84905704899     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5538     Document Type: Article

References (51)

1. Alisi A and Nobili V. Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. Nutrition 28: 722-726, 2012.
2. Assy N. Nutritional recommendations for patients with non-alcoholic fatty liver diseases. World J Gastroenterol 17: 3375-3376, 2011.
3. Bellentani S and Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 8 Suppl 1: S4-S8, 2009.
4. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, and Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395, 2004.
5. Cerda B, Ceron JJ, Tomas-Barberan FA, and Espin JC. Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J Agric Food Chem 51: 3493-3501, 2003.
6. Cerda B, Llorach R, Ceron JJ, Espin JC, and Tomas-Barberan FA. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 42: 18-28, 2003.
7. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, and Diehl AM. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 274: 5692-5700, 1999.
8. Chen B, Tuuli MG, Longtine MS, Shin JS, Lawrence R, Inder T, Michael, and Nelson D. Pomegranate juice and punicalagin attenuate oxidative stress and apoptosis in human placenta and in human placental trophoblasts. Am J Physiol Endocrinol Metab 302: E1142-E1152, 2012.
9. Choudhury M, Jonscher KR, and Friedman JE. Reduced mitochondrial function in obesity-associated fatty liver: SIRT3 takes on the fat. Aging (Albany NY) 3: 175-178, 2011.
10. Eberle D, Hegarty B, Bossard P, Ferre P, and Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86: 839-848, 2004.
11. Endo EH, Cortez DA, Ueda-Nakamura T, Nakamura CV, and Dias Filho BP. Potent antifungal activity of extracts and pure compound isolated from pomegranate peels and synergism with fluconazole against Candida albicans. Res Microbiol 161: 534-540, 2010.
12. Fan JG and Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50: 204-210, 2009.
13. Feldstein AE and Bailey SM. Emerging role of redox dysregulation in alcoholic and nonalcoholic fatty liver disease. Antioxid Redox Signal 15: 421-424, 2011.
14. Frederico MJ, Vitto MF, Cesconetto PA, Engelmann J, De Souza DR, Luz G, Pinho RA, Ropelle ER, Cintra DE, and De Souza CT. Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice. Scand J Gastroenterol 46: 1381-1388, 2011.
15. Gambino R, Musso G, and Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 15: 1325-1365, 2011.
16. Garedew A, Andreassi C, and Moncada S. Mitochondrial dynamics, biogenesis, and function are coordinated with the cell cycle by APC/C CDH1. Cell Metab 15: 466-479, 2012.
17. Gornicka A, Morris-Stiff G, Thapaliya S, Papouchado BG, Berk M, and Feldstein AE. Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. Antioxid Redox Signal 15: 437-445, 2011.
18. Hao J, Shen W, Yu G, Jia H, Li X, Feng Z, Wang Y, Weber P, Wertz K, Sharman E, and Liu J. Hydroxytyrosol promotes mitochondrial biogenesis and mitochondrial function in 3T3-L1 adipocytes. J Nutr Biochem 21: 634-644, 2010.
19. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, and Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44: 1167-1174, 2006.
20. Heber D. Multitargeted therapy of cancer by ellagitannins. Cancer Lett 269: 262-268, 2008.
21. Hoekstra LT, de Graaf W, Nibourg GA, Heger M, Bennink RJ, Stieger B, and van Gulik TM. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 257: 27-36, 2013.
22. Hotamisligil GS. Inflammation and metabolic disorders. Nature 444: 860-867, 2006.
23. Kim JB, Wright HM, Wright M, and Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA 95: 4333-4337, 1998.
24. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, Yang US, Yu DY, and Cheong J. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 132: 1955-1967, 2007.
25. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R, and Nakamuta M. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 21: 507-511, 2008.
26. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, and Weinman SA. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280: 37481-37488, 2005.
27. Lam BP and Younossi ZM. Treatment regimens for nonalcoholic fatty liver disease. Ann Hepatol 8 Suppl 1: S51-S59, 2009.
28. Lazarin Mde O, Ishii-Iwamoto EL, Yamamoto NS, Constantin RP, Garcia RF, da Costa CE, Vitoriano Ade S, de Oliveira MC, and Salgueiro-Pagadigorria CL. Liver mitochondrial function and redox status in an experimental model of non-alcoholic fatty liver disease induced by monosodium L-glutamate in rats. Exp Mol Pathol 91: 687-694, 2011.
29. Liu J, Jin X, Yu CH, Chen SH, Li WP, and Li YM. Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis. J Gastroenterol Hepatol 25: 613-618, 2010.
30. Louet JF, Hayhurst G, Gonzalez FJ, Girard J, and Decaux JF. The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMPresponse element-binding protein (CREB). J Biol Chem 277: 37991-38000, 2002.
31. Mantena SK, King AL, Andringa KK, Eccleston HB, and Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol-and obesityinduced fatty liver diseases. Free Radic Biol Med 44: 1259-1272, 2008.
32. Matsuda M, Korn BS, Hammer RE, Moon YA, Komuro R, Horton JD, Goldstein JL, Brown MS, and Shimomura I. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev 15: 1206-1216, 2001.
33. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, and Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55: 429-436, 2012.
34. Nakatani T, Tsuboyama-Kasaoka N, Takahashi M, Miura S, and Ezaki O. Mechanism for peroxisome proliferatoractivated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes. J Biol Chem 277: 9562-9569, 2002.
35. Nohturfft A, Brown MS, and Goldstein JL. Sterols regulate processing of carbohydrate chains of wild-type SREBP cleavage-activating protein (SCAP), but not sterol-resistant mutants Y298C or D443N. Proc Natl Acad Sci USA 95: 12848-12853, 1998.
36. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, and George J. Omega-3 supplementation and nonalcoholic fatty liver disease: a systematic review and metaanalysis. J Hepatol 56: 944-951, 2012.
37. Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth FW, and Ibdah JA. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 52: 727-736, 2010.
38. Shen W, Hao J, Tian C, Ren J, Yang L, Li X, Luo C, Cotma CW, and Liu J. A combination of nutriments improves mitochondrial biogenesis and function in skeletal muscle of type 2 diabetic Goto-Kakizaki rats. PLoS One 3: e2328, 2008.
39. Song CY, Shi J, Zeng X, Zhang Y, Xie WF, and Chen YX. Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway. Toxicol In Vitro 27: 1065-1071, 2013.
40. Song S, Attia RR, Connaughton S, Niesen MI, Ness GC, Elam MB, Hori RT, Cook GA, and Park EA. Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1 alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. Mol Cell Endocrinol 325: 54-63, 2010.
41. Sun L, Shen W, Liu Z, Guan S, Liu J, and Ding S. Endurance exercise causes mitochondrial and oxidative stress in rat liver: effects of a combination of mitochondrial targeting nutrients. Life Sci 86: 39-44, 2010.
42. Sutti S, Jindal A, Locatelli I, Vacchiano M, Gigliotti L, Bozzola C, and Albano E. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology 2013 [Epub ahead of print]; DOI: 10.1002/hep.26749.
43. Thoma C, Day CP, and Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 56: 255-266, 2012.
44. Tuyama AC and Chang CY. Non alcoholic fatty liver disease. J Diabetes 4: 266-280, 2012.
45. Tziomalos K, Athyros VG, and Karagiannis A. Nonalcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 10: 162-172, 2012.
46. Valenti D, Manente GA, Moro L, Marra E, and Vacca RA. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway. Biochem J 435: 679-688, 2011.
47. Valentin-Vega Y and Kastan MB. A new role for ATM: regulating mitochondrial function and mitophagy. Autophagy 8: 840-841, 2012.
48. Vial G, Dubouchaud H, Couturier K, Cottet-Rousselle C, Taleux N, Athias A, Galinier A, Casteilla L, and Leverve XM. Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J Hepatol 54: 348-356, 2011.
49. Wang Q, Jiang L, Wang J, Li S, Yu Y, You J, Zeng R, Gao X, Rui L, Li W, and Liu Y. Abrogation of hepatic ATPcitrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology 49: 1166-1175, 2009.
50. Yasari S, Prud'homme D, Wang D, Jankowski M, Levy E, Gutkowska J, and Lavoie JM. Exercise training decreases hepatic SCD-1 gene expression and protein content in rats. Mol Cell Biochem 335: 291-299, 2010.
51. Zou X, Feng Z, Li Y, Wang Y, Wertz K, Weber P, Fu Y, and Liu J. Stimulation of GSH synthesis to prevent oxidative stress-induced apoptosis by hydroxytyrosol in human retinal pigment epithelial cells: activation of Nrf2 and JNK-p62/SQSTM1 pathways. J Nutr Biochem 23: 994-1006, 2012.